NLRP3 and macrophage activation syndrome: However, pharmacological inhibition of the NLRP3 inflammasome, caspase-1 or the IL-1 receptor did not prevent development of MAS symptoms, despite a reduction in plasma IL-18 levels following inhibition of NLRP3 or caspase-1.